Pharma sector boom puts pressure on compliance to counter financial crime
By 
Ruth Prickett2025-12-04T22:15:00
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
Globally, the sector is booming. According to Robinson Brothers website, the global pharmaceutical industry is forecast to be worth $1.6 trillion this year. Costs are also high. It typically costs up to £1.15bn to develop and market a new treatment – which can take more than 12 years – and 95 percent of all experimental medicines studied for human treatment fail to achieve approval.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleU.K. asset managers to focus on investor engagement outcomes under new reporting guidance
Asset managers reporting under the U.K.’s updated Stewardship Code starting Jan 1 should focus on engagement outcomes and evidence of impact. New guidance from the U.K. financial regulator offers case studies and checklists to support compliance.
-
ArticleNew regulatory regimes for U.K. and EU ESG ratings firms could increase compliance costs
Environmental ratings are becoming big business as companies seek proof of sustainable and socially beneficial conduct. Firms that issue ratings on environmental, social and governance (ESG) performance are set to be regulated in the EU and U.K.
-
ArticleU.K. Cyber Security and Resilience bill set to regulate critical infrastructure suppliers
Suppliers to the U.K. critical infrastructure will face new regulations to ensure they are protected from cyberattacks. The Cyber Security and Resilience Bill, introduced on November 12, also raises penalties for breaches and expands regulator powers to label certain suppliers as critical.
More from Regulatory Policy
-
ArticleEU loosens AI and data rules
Europe has been at the forefront of designing strong—but flexible—rules around data use and the safe development of AI, but the EU recently announced plans to simplify some key measures around data privacy and AI governance, which have met with mixed responses.
-
PremiumQ&A with FINRA’s Greg Ruppert on the organization’s use of Artificial Intelligence
Greg Ruppert, Chief Regulatory Operations Officer at the Financial Industry Regulatory Authority (FINRA), recently shared insights with Compliance Week regarding the self-regulatory organization’s use of Artificial Intelligence in monitoring trends in the market, spotting threats, and keeping its members informed.
-
PremiumEU financial firms must prepare now for new rules on critical third-party arrangements
European banks and financial institutions must prepare now for stringent new rules on third-party suppliers.